More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.65B
EPS
-0.19
P/E ratio
--
Price to sales
6.24
Dividend yield
--
Beta
0.769663
Previous close
$23.47
Today's open
$23.61
Day's range
$23.05 - $23.98
52 week range
$15.96 - $29.02
show more
CEO
Samantha Du
Employees
1784
Headquarters
Shanghai,
Exchange
NASDAQ Global Market
Shares outstanding
112444835
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
Zai Lab looks underappreciated as the wholly owned developer of zoci, a potential DLL3 treatment backbone, rather than merely a China distributor. Amgen and Boehringer are funding zoci combination studies; first-line data showed an 81.8% response rate across 33 evaluable patients. I estimate roughly ten quarters of debt-adjusted cash runway at elevated trial spending, while management expects product revenue growth to return in 2027.
Seeking Alpha • Nov 16, 2026

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis.
Benzinga • Nov 13, 2026

Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Seeking Alpha • Nov 13, 2026

Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally discovered, long-acting IL-13/IL-31 receptor alpha (Rα) bispecific antibody. Findings from the study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scien.
Business Wire • Nov 13, 2026

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease. Zai Lab Products Newly.
Business Wire • Nov 14, 2026

Zai Lab Announces Participation in Investor Conferences in November 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November 2026: UBS Global Biopharma Conference Date: November 17, 2026 Event Format: 1-on-1 meetings only Location: London, UK Jefferies Global Healthcare Conference in London Date: November 18 and 19, 2026 Fireside Chat: Wednesday, November 18, 2026 at 10:30AM GMT Event Format: Pre.
Business Wire • Nov 13, 2026

Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
The consensus price target hints at a 40.2% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Nov 10, 2026

Zai Lab Q3 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate toward potential U.S. regulatory submissions next year.
MarketBeat • Nov 7, 2026

Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026, along with recent product highlights and corporate updates. “We are approaching a defining period for Zai Lab, as we advance toward bringing our first internally developed innovative medicines to patients globally,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “The.
Business Wire • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Zai Lab Limited commission-free¹. Build wealth for the long term using automated trading and transfers.